NEJM Interviews

Por: NEJM Group
Insightful conversations with leading experts in the field of health care, medical research, policy, and more from the New England Journal of Medicine (NEJM). Each episode examines the many complexities found at the junction of medicine and society.
916 episodios disponibles

Latest episodes of the podcast NEJM Interviews

Mostrando página 4 de 46

NEJM at AHA — CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy 15/11/2024
NEJM at AHA — Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity 15/11/2024
NEJM at AHA — Intensive Blood-Pressure Control in Patients with Type 2 Diabetes 15/11/2024
NEJM Interview: Heather Hsu on an institutional conference series that provides opportunities for addressing the adverse effects of bias and medical racism. 13/11/2024
The Marburg Virus Outbreak in Rwanda 06/11/2024
NEJM Interview: Vincent Guilamo-Ramos on the need to rethink the response to HIV in Latino communities. 06/11/2024
NEJM Interview: Liam McCoy on concerns about the implementation of large language models in note writing and related clinical tasks. 30/10/2024
NEJM Interview: Mark Wicclair on approaches to protecting both physicians’ conscience and patients’ health. 23/10/2024
NEJM Interview: Jose Figueroa on the potential effects of the results of the 2024 elections on health care access, affordability, and equity. 16/10/2024
NEJM Interview: Jean Nachega on the mpox Public Health Emergency of International Concern. 09/10/2024
NEJM Interview: Jonathan Oberlander on the implications of the 2024 U.S. elections for health care reform. 02/10/2024
NEJM at ESMO — Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma 15/09/2024
NEJM at ESMO — Phase 3 Trial of Cabozantinib in Advanced Neuroendocrine Tumors 15/09/2024
NEJM at ESMO — Overall Survival with Pembrolizumab in Early-Stage Triple- Negative Breast Cancer 14/09/2024
NEJM at ESMO — Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer 14/09/2024
NEJM at ESMO — Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma 14/09/2024
NEJM at ESMO — Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer 14/09/2024
NEJM at ESMO — Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma 14/09/2024
NEJM at ESMO — Ponsegromab in Cancer Cachexia 13/09/2024
NEJM at ESMO — Pembrolizumab in HER2+ Gastric Cancer 13/09/2024
« Primera ‹ Anterior 1 2 3 4 5 6 ... 46 Siguiente › Última »
© 2003-2026 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA